1H-Imidazole-1-propanamine → 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide

Participants

Reaction Steps

In a similar manner to that described in example 196, from ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (10 mg, 0.028 mmol) described in example 92 and [3-(1H-imidazol-1-yl)propyl]amine (48 mg, 0.0384 mmol), was prepared 7-[(4-fluorophenyl)methyl]-4-hydroxy-N-[3-(1H-imidazol-1-yl)propyl]-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (4 mg, 33% yield), as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.36 (br s, 1 H), 8.59 (s, 1 H), 7.74 (s, 1 H), 7.42 (s, 1 H), 7.18-7.14 (m, 2 H), 7.12 (s, 1 H), 7.05-7.01 (m, 3 H), 4.15 (s, 2 H), 4.11-4.07 (m, 2 H), 3.59 (s, 3 H), 3.51-3.45 (m, 2 H), 2.19-2.12 (m, 2 H); MS m/z 436 (M+1).

Provenance & Evidence